EB Research Partnership Announces the 3rd Annual Believe in Brady on April 7 in Houston
April 01, 2019 14:19 ET
|
EB Research Partnership
HOUSTON, April 01, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), is...
ESPN’s Scott Van Pelt to Host 2nd Annual Change for Charley on March 9 in Chicago
March 01, 2019 09:30 ET
|
EB Research Partnership
CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing the devastating and...
EB Research Partnership Announces the 2nd Annual Plunge for Elodie on March 2 in Wellesley
February 21, 2019 09:04 ET
|
EB Research Partnership
BOSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), the largest nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), is...
EBRP, EBRF and other Global EB Charities Collaborate to Announce $1 Million Award for EB Simplex
December 21, 2018 09:22 ET
|
EB Research Partnership
NEW YORK, Dec. 21, 2018 (GLOBE NEWSWIRE) -- EB Research Partnership, the largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB),...
EB Research Partnership and EB Research Foundation Join Forces to Advance Breakthroughs in Epidermolysis Bullosa Research
August 27, 2018 19:00 ET
|
EB Research Partnership
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- EB Research Partnership (EBRP), based in New York, and Australian-based EB Research Foundation, today announced a global collaboration to accelerate their...
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
June 28, 2018 07:00 ET
|
ProQR Therapeutics N.V.
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a...
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
June 12, 2018 07:00 ET
|
ProQR Therapeutics N.V.
The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018 LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) --...
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
April 30, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
November 29, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA.QR-313 also received U.S. ODD from the FDA in September...
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
September 19, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA, representing the fifth program in the Company’s pipeline to receive...